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Background. In Mexico, the lifetime risk of dying from maternal causes is 1 in 370 compared to 1 in 2,500 in the U.S. Although
national efforts have been made to improve maternal services in the last decade, it is unclear if Millennium Development Goal
5 - to reduce maternal mortality by three-quarters by 2015 - will be met. Methodology/Principal Findings. We developed an
empirically calibrated model that simulates the natural history of pregnancy and pregnancy-related complications in a cohort
of 15-year-old women followed over their lifetime. After synthesizing national and sub-national trends in maternal mortality,
the model was calibrated to current intervention-specific coverage levels and validated by comparing model-projected life
expectancy, total fertility rate, crude birth rate and maternal mortality ratio with Mexico-specific data. Using both published
and primary data, we assessed the comparative health and economic outcomes of alternative strategies to reduce maternal
morbidity and mortality. A dual approach that increased coverage of family planning by 15%, and assured access to safe
abortion for all women desiring elective termination of pregnancy, reduced mortality by 43% and was cost saving compared to
current practice. The most effective strategy added a third component, enhanced access to comprehensive emergency
obstetric care for at least 90% of women requiring referral. At a national level, this strategy reduced mortality by 75%, cost less
than current practice, and had an incremental cost-effectiveness ratio of $300 per DALY relative to the next best strategy.
Analyses conducted at the state level yielded similar results. Conclusions/Significance. Increasing the provision of family
planning and assuring access to safe abortion are feasible, complementary and cost-effective strategies that would provide the
greatest benefit within a short-time frame. Incremental improvements in access to high-quality intrapartum and emergency
obstetric care will further reduce maternal deaths and disability.
Citation: Hu D, Bertozzi SM, Gakidou E, Sweet S, Goldie SJ (2007) The Costs, Benefits, and Cost-Effectiveness of Interventions to Reduce Maternal
Morbidity and Mortality in Mexico. PLoS ONE 2(8): e750. doi:10.1371/journal.pone.0000750
INTRODUCTION
Every year over half a million women die from complications of
pregnancy and childbirth [1]. The maternal mortality ratio (MMR)
forMexicoisestimatedat83maternaldeathsper100,000livebirths,
nearly five times the ratio reported for the United States, and the
lifetime risk of dying from maternal causes is 1 in 370 [1]. Within
Mexico,thereissubstantialheterogeneityinmaternalmortality,with
the highest rates observed in Guerrero and the State of Mexico and
the lowest rates in Colima and Sonora [2,3].
Significant national efforts have been made to improve the cover-
age, quality, and range of maternal services for women in Mexico
such as Fair Start in Life (Arranque Parejo en la Vida), the People’s
Health Insurance (Seguro Popular de Salud) and the Oportunidades
(formerly PROGRESA) program [4]. To assist in programmatic and
budgetary planning, the financial costs of providing the package of
services included in the World Health Organization’s (WHO)
Mother Baby Package (MBP) at recommended coverage levels were
estimated for Morelos state by the National Institute of Public Health
[4,5]. To date, however, few cost-effectiveness analyses of safe
motherhoodstrategiesinMexicohavebeenconductedfromasocietal
perspective and long-term investment approach.
Information on the cost-effectiveness of alternative strategies to
improve maternal care can serve as one important policy input to
guide decisions on how to achieve Millennium Development Goal
5 (MDG5) of reducing the maternal mortality ratio by three-
quarters between 1990 and 2015. Cost-effectiveness analyses can
enhance and complement a national strategy to mount political
commitment and evidence-based action. A modeling approach
within a decision-analytic framework can combine information
from a wide variety of sources, extrapolate costs and health effects
beyond the time horizon of a single clinical study, and evaluate
multiple potential interventions packaged into strategies. Using the
best available clinical and epidemiologic data from Mexico and
Latin America, we adopt this approach to conduct a cost-
effectiveness analysis of alternative strategies to reduce maternal
mortality and morbidity in Mexico.
METHODS
Analytic Overview
We conducted a cost-effectiveness analysis of alternative maternal
morbidity and mortality reduction strategies in Mexico using
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PLoS ONE | www.plosone.org 1 August 2007 | Issue 8 | e750a computer-based model that simulates the natural history of
pregnancy (both planned and unintended) and pregnancy-related
complications in a cohort of 15-year-old women followed over
their lifetime. Using regional and country-specific data, we
compare the health outcomes and costs associated with the
current maternal health intervention coverage levels (referred to as
current standard of care or current practice) in Mexico; upgrading
selected strategies to achieve coverage levels recommended in the
WHO Mother Baby Package (MBP) standard of care; and
increasing coverage of selected interventions alone (e.g., enhanced
access to safe abortion) and in the context of strategic packages
(e.g., increased family planning, enhanced safe abortion, improved
access to emergency obstetric services). Model outcomes include
intermediate clinical events (e.g., unsafe abortion, severe pre-
eclampsia/eclampsia, obstructed labor, hemorrhage, and sepsis)
and long-term outcomes (e.g., life expectancy, disability-adjusted
life expectancy, and lifetime costs). We follow recommendations in
published guidelines for standardizing economic evaluations [6–9].
The comparative performance of alternate strategies is described
using the incremental cost-effectiveness ratio, defined as the
additional cost of a specific strategy divided by its additional
clinical benefit, compared with the next least expensive strategy.
Sensitivity analyses assess the effect of varying baseline estimates
and assumptions on our results.
The Model
The Maternal Health Policy Model is a computer-based state-
transition model that simulates the natural history of pregnancy
(both planned and unplanned) and pregnancy-related complica-
tions in a representative cohort of sexually-active Mexican women.
Health states in the model reflect important characteristics that
affect mortality, quality of life and resource use. (Figure 1) The
time horizon incorporates a woman’s entire lifetime and is divided
into equal increments during which women transition from one
health state to another. A cohort of 100 000 sexually-active 15-
year-old girls enters the model, and faces a risk of becoming
pregnant each year. The probability of becoming pregnant
depends on a woman’s age, history of pregnancy-related
complications, and use of contraception. Women who become
pregnant may experience a miscarriage or have an elective
abortion, a fraction of which are unsafe (defined as a medically or
surgically induced abortion performed by an untrained person),
conferring a higher risk of death and complications. A woman who
remains pregnant may have an uncomplicated course or she may
develop a pregnancy- or delivery-related complication (e.g., severe
preeclampsia/eclampsia, obstructed labor, postpartum hemor-
rhage, sepsis, sexually transmitted infection) associated with a risk
of death and long-term sequelae (e.g., infertility, neurological
sequelae, rectovaginal fistula, severe anemia). We assume that
infertility can result following a sexually transmitted infection,
unsafe abortion, or sepsis; women with severe anemia have
a higher relative risk for death from maternal complications; and
all women face age-specific risks of dying from other causes.
Interventions can be applied at different time points in
a woman’s reproductive life and pregnancy (Figure 2) and
include: (1) provision of family planning; (2) safe abortion; (3)
prenatal care (e.g., four to six prenatal visits including physical
exam, urine protein screen, screening and treatment for anemia
and syphilis, iron/folate supplementation, tetanus vaccination, and
if indicated, treatment for sexually transmitted infections; (4) high-
quality intrapartum care including access to skilled attendants and
emergency obstetric care (e.g., timely access to a facility with
surgical expertise, critical care capability including blood transfu-
sions, and ability to manage serious obstetric complications that
can cause death); and (5) postpartum care (e.g., postnatal visit
including physical exam, iron and vitamin A supplementation).
The impact of an overall strategy is determined by the
effectiveness of each individual intervention, the set of interven-
tions included in the package of services, and the coverage
achieved. (Table 1) When multiple interventions are evaluated
within a single strategy, we assume interventions that target different
maternal complications have an additive effect whereas those that
act on the same maternal complication have a multiplicative effect.
The effectiveness of family planning is estimated as a function of
the performance and coverage level of the contraceptive method.
The effect of other interventions is modeled as a reduction in the
case fatality rate and/or morbidity risk of a specific maternal
complication(s).
In an initial analysis we simulate three scenarios to provide
insight into the magnitude of what has been achieved by Mexico
with the current standard of maternal care, and to assess the
impact of upgrading selected strategies to the coverage levels
recommended in the WHO MBP. In this analysis we use historical
data to simulate natural history (i.e., absence of significant
maternal care) in which coverage is assumed to be 14% for skilled
birth attendance. We then simulate access to services and
increased coverage levels over time to assess the incremental costs
and benefits of the current standard of care in Mexico, in which
coverage for primary level interventions is 68%, skilled attendance
is 86%, the coverage of hospital-level interventions is 81%, and
coverage for family planning is 59% in women 20 years of age and
older and 18% for women under 20 years of age [10–13]. Finally,
we comparatively assess an upgrade to the standard of care and
coverage levels recommended in the MBP with a coverage of 90%
for all interventions except family planning, whose coverage is
increased from 59% to 74% in women age 20 and older, and from
18% to 33% in women younger than age 20 [4,5].
In a second analysis, considered to be our base case analysis, we
use the current standard of care in Mexico as the baseline
comparator and assess the incremental cost-effectiveness of
increasing coverage of individual interventions or subsets of
interventions. We consider access to comprehensive emergency
obstetrical care (EmOC) to be access to a facility with surgical
expertise (e.g., cesarean section), critical care capability including
blood transfusions, and ability to manage serious obstetric
complications. However, we recognize ensuring high-quality
intrapartum care will require different approaches and invest-
ments depending on the local situation and setting in the
individual states within Mexico. Accordingly, we define enhanced
access to comprehensive EmOC as an investment in any of the
following: (a) a program to improve appropriate and timely
referral rates; (b) improved transportation to facilitate rapid access
to a hospital with a blood supply and surgical expertise; (c) new
technologies to stabilize a woman en route to emergency care; (d)
improved quality of health services for management of severe
obstetrical complications.
Model Input Data
A detailed summary of selected variable estimates and their
plausible ranges is available in the Appendix S1. We estimated
an annual rate of pregnancy under ‘‘natural fertility’’ conditions of
31% using data from Afghanistan, where abortion is illegal and
access to modern contraception is limited [13–15]. In accordance
with the 2004 Population Reference Bureau World Data, we
assumed 68% of women ages 20–45 years use some method of
birth control with 9% employing traditional methods (i.e.,
withdrawal or periodic abstinence) and 59% using modern
methods (12% oral contraceptives, 6% condoms, 24% intrauterine
Reducing Maternal Mortality
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partners sterilized). We assumed a lower uptake of contraception
among women ,20 years age with 12.3% employing traditional
methods and 17.7% using modern methods. We assumed 15% of
all pregnancies result in a miscarriage (of which 33% require
further management) [16,17] and 17% end in abortion [18] (of
which 50% are unsafe) [19,20]. There is considerable uncertainty
in estimates of unsafe abortion (in part due to underreporting), and
thus we varied the risk of abortion, the proportion that are unsafe,
and the abortion-related mortality rate in sensitivity analyses.
Because Mexico-specific data on the incidence of maternal
complications and complication-related deaths are limited, we
relied in part on regional estimates for Latin America and
Caribbean region from the Global Burden of Disease (GBD) Study
[21,22]. The case fatality rate (CFR) for each maternal
complication under ‘‘natural history’’ conditions was derived by
assuming the ‘‘natural history’’ CFR was a function of the current
CFR reported for Latin America and Caribbean, the maternal
complication rate, and the coverage rate and effectiveness of
applicable maternal health interventions [10–13,21,23–37]. Effec-
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Figure 1. Schematic of Natural History Model. Upper Panel. The ovals represent the key health states used in the model. Nonpregnant 15-year-old
women enter the model and are subject to an annual risk of pregnancy. Once pregnant, a woman may experience a miscarriage, elect to undergo an
abortion, develop a maternal complication, or have an uncomplicated pregnancy and delivery. A small proportion of nonpregnant women will have
severe anemia and subsequently will have a higher risk of mortality from maternal complications. Lower Panel. Every pregnant woman is subject to
a risk of developing major maternal complications, such as a sexually transmitted infection with chlamydia or gonorrhea, sepsis, postpartum
hemorrhage, severe preeclampsia/eclampsia, or obstructed labor. Each maternal complication is associated with a further risk of death or long-term
sequelae (e.g., infertility, severe anemia, neurological sequelae, rectovaginal fistula), which are associated with a decrement in health-related quality
of life and costs related to either management or treatment.
doi:10.1371/journal.pone.0000750.g001
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PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e750tiveness data were from the published literature, using randomized
controlled trials whenever possible, followed by prospective cohort
studies and expert opinion [23–37]. When an intervention lacked
a clear evidence base, we conservatively assumed there was no
effect on mortality. Coverage rates for prenatal care, deliveries
assisted by skilled attendants, and facility-based deliveries were
Well 
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Pregnant 
Uncomplicated 
Pregnancy and 
Delivery 
Complications 
Abortion 
-Safe/unsafe  Intervention: 
Family Planning 
Intervention: 
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Treatment of severe 
anemia 
Intervention: 
Postnatal 
Care 
Intervention: 
Management of 
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labor, postpartum 
hemorrhage, sepsis 
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Safe abortion 
Figure 2. Schematic of Modeled Interventions. Interventions are applied to different points along the clinical course of pregnancy and delivery.
Prenatal care, the treatment of sexually transmitted infections, and the management of severe anemia apply throughout the three trimesters of
pregnancy prior to labor and delivery. Safe abortion applies to the first trimester of pregnancy. Hospital-based interventions such as the management
of severe preeclampsia/eclampsia, obstructed labor, postpartum hemorrhage, and sepsis apply to the periods of labor and delivery as well as
postpartum.
doi:10.1371/journal.pone.0000750.g002
Table 1. Impact and coverage levels of interventions.*
..................................................................................................................................................
Intervention
Impact on Mortality or
Morbidity Evidence Level{
Current Coverage in
Mexico (%)
Recommended Coverage in
MBP Standard of Care (%)
Family planning (,20 years) Both C 18 33
Family planning ($20 years) Both C 59 74
Prenatal care Uncertain None 68 90
Treatment of severe anemia Mortality C 68 90
Treatment of symptomatic STI’s Morbidity B 68 90
Skilled birth attendants Mortality D 86 90
Safe abortion Both B 50 {
Management of complications
Severe Preeclampsia/Eclampsia Mortality A 81 90
Obstructed labor Both A 81 90
Postpartum hemorrhage Mortality A 81 90
Sepsis Mortality A 81 90
Postpartum care Uncertain None 68 90
*MBP = Mother baby package; STI =sexually transmitted infection
{Refers to whether direct or indirect evidence exists for the impact of the intervention on maternal mortality or morbidity. Evidence level is interpreted as follows for
purposes of this analysis: A indicates that evidence comes from randomized controlled trial(s) conducted in a developed country setting, but the actual effectiveness of
the intervention could be lower in developing countries due to reduced access and quality of care; B indicates that evidence comes from randomized controlled trial(s)
conducted in a developed country setting, but actual intervention effectiveness is likely similar in developed and developing countries; C indicates that evidence is
based on prospective cohort studies, observational and case control studies; D indicates an assumption is based solely on expert opinion; and none indicates an
absence of evidence. The absence of evidence for an impact on mortality or morbidity is not intended to be interpreted as there is no effect, but indicates the absence
of data to support an effect.
{Provision of safe abortion is not a component of the MBP. Since the MBP strategy represents an upgrade from current practice patterns, however, coverage of safe
abortion remains at the current practice level of 50%.
doi:10.1371/journal.pone.0000750.t001
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PLoS ONE | www.plosone.org 4 August 2007 | Issue 8 | e750taken from Mexico-specific estimates [10–13]. Risk for long-term
complications, disability weights, and duration of disability were
estimated from the GBD study [21].
Direct medical costs were based on a comprehensive study
assessing the costs of interventions included in the WHO MBP in
Morelos State, Mexico [4,22]. Data included personnel, services,
drugs, and both inpatient and outpatient services for three
different levels of care: rural health center, urban health center,
and hospital. Interventions such as treatment for severe anemia,
treatment of sepsis, skill attendants, and family planning cost less
when delivered in center-based settings compared with hospital-
level settings. Costs related to the treatment of selected long-term
complications associated with infertility, neurologic sequelae, and
obstetric fistula were estimated using published studies conducted
in other countries and scaled to approximate healthcare costs in
Mexico [38–42]. Productivity costs associated with premature
death were explored using sensitivity analysis [43,44]. All costs
were expressed in 2001 U.S. dollars. Also see Appendix S1 for
additional information.
State-Specific Analyses
To provideinsightinto howmaternal mortality trendsdifferbystate,
wegrouped statesinto three categoriesusing the‘‘marginalityindex’’
constructed by the National Institute on Statistics and Geography,
a composite index that considers nine indicators of socioeconomic
status of the community (listed in the Appendix S1), and ranges
from low (best-off) marginality to very high (worst-off) marginality
[45]. Using the death registration records and the population
statisticsforyear2000 providedbythe MinistryofHealth inMexico,
we estimated disability-adjusted life years (DALY) attributable to the
five Global Burden of Disease categories considered to be maternal
conditions, by state and level of marginality. We then assessed the
burden of maternal-related disease at the state level, conducted
a time-trend analysis for a ten year period (1992–2002), and
conducted subnational cost-effectiveness analyses.
RESULTS
Model Performance and Face Validity
The model predicted a total fertility rate and crude birth rate of
2.7 births per woman and 21 births per 1,000 population
compared to 2.6 births per woman and 21 to 24 births per
1,000 population reported for Mexico by UNICEF, WHO, and
the Population Reference Bureau [11,13,46]. Model output
(maternal deaths, live births) was used to generate a MMR for
Mexico. After adjusting for the maternal complications included in
the analysis, the model predicted an MMR of 85, closely
approximating the MMR of 83 reported by the WHO for Mexico
in 2000 [1].
Clinical Outcomes, Costs, and Cost-Effectiveness
Analysis
Table 2 shows the percent reduction in mortality and morbidity
associated with the current standard of maternal care (i.e., current
effective coverage levels) and by upgrading selected strategies to
coverage levels recommended in the MBP standard of care,
compared with a historical scenario of no maternal care. Although
the mortality reduction with the current standard of care in
Mexico has been substantial, upgrading to the coverage levels in
the MBP standard of care reduces the number of deaths for a cohort
of 100,000 women, from 175 to 92, and cases of serious morbidity
from 4,149 to 2,755, representing an approximate additional 50%
reduction in mortality. In addition to being more effective than
current practice, upgrading to the coverage levels in the MBP
standard of care reduced the per-person lifetime costs from $503 to
$372, and had an incremental cost-effectiveness ratio of $550 per
life year saved (YLS) and $390 per disability-adjusted life year
(DALY) averted.
Table 3 shows the results of a second analysis in which we
assessed the incremental benefits and cost-effectiveness of in-
creasing coverage of individual interventions or subsets of
interventions, compared to the current standard of care in Mexico.
Each of the strategies shown was more effective and less costly
than current practice. A combined approach of (1) increasing
family planning from 59% to 74% in women age 20 and older,
and from 18% to 33% in women younger than age 20, and (2)
assuring access to safe abortion for all women who electively
terminate a pregnancy, provided a 43% reduction in mortality and
was cost saving relative to current practice. The most effective
strategy added a third component to these two interventions, by (3)
providing access to high-quality intrapartum care for all pregnant
women and enhancing access to comprehensive emergency
obstetric care for at least 90% of women. This strategy provided
a 75% reduction in maternal mortality, a 47% reduction in
morbidity, and had an incremental cost-effectiveness ratio of $300
per DALY averted relative to the next best strategy. Although
other strategies shown were formally dominated by the provision
of these three interventions, they were all cost saving relative to
current practice in Mexico. For the 4 most effective strategies
shown in Table 3, the cost savings over the lifetime of a cohort of
100,000 women would exceed $10 million.
Sensitivity Analysis
Cost-effectiveness results were most sensitive to the cost of
increasing coverage of interventions above and beyond the current
practice in Mexico. The magnitude of the reduction in maternal
mortality was most sensitive to the assumptions about the baseline
effective coverage rates assumed in the base case, the risk of
Table 2. Benefits, costs, and cost-effectiveness of current practice in Mexico (compared with no maternal care), and upgrading to
the coverage rates in the WHO Mother Baby Package (MBP) standard of care.*
..................................................................................................................................................
Strategy
Mortality (#
deaths per
100,000)
Morbidity (#
events per
100,000)
Additional reduction
in mortality vs.
natural history, %
Additional reduction
in morbidity vs.
natural history, %
Costs (average
discounted
lifetime)
Life expectancy
(average,
discounted)
ICER
($/LY)
ICER ($/
DALY)
Natural History 1,556 10,262 --- --- $237.16 28.4010 --- ---
Current Practice in Mexico 175 4,149 88.7 59.6 $502.87 28.6321 {{
MBP Standard of Care 92 2,755 94.1 73.2 $371.82 28.6463 550 390
*LY=Life years, DALY=Disability adjusted life years, ICER=incremental cost-effectiveness ratio; MBP=Mother Baby Package
{Current practice in Mexico (i.e., average coverage rates associated with status quo) is dominated by the coverage rates recommended in the MBP standard of care since
the MBP is less costly and more effective. (see Methods for details)
doi:10.1371/journal.pone.0000750.t002
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PLoS ONE | www.plosone.org 5 August 2007 | Issue 8 | e750mortality due to unsafe abortion, and the effectiveness of maternal
health interventions.
Figure 3 shows how the incremental cost-effectiveness ratio
associated with the most effective strategy changes as we vary the
additional costs associated with providing enhanced access to
comprehensive emergency obstetric care. We express this as
a composite cost of a successfully referred woman, and assume it
includes the costs required for ensuring recognition of the need for
referral, expedient transport, and ultimate access to an appropriate
facility capable of comprehensive EmOC. We estimate that up to
18.5% of pregnant women ultimately need emergency care, from
20% to 30% will be referred, and vary the cost per successful
referral from $18.50 (base case) to $370. Provided the incremental
cost was below $120 per successfully referred woman, the most
effective strategy would be associated with a lower average per-
woman lifetime cost than that of current practice. Even at a cost of
$185 per successfully referred woman, the incremental cost-
effectiveness ratio was below the Mexico-specific Gross Domestic
Product (GDP) per capita ($6,172) [47], and would therefore be
considered very cost-effective [48].
Because of the uncertainty in the underlying parameters and
assumptions around abortion, we conducted a sensitivity analysis
in which we varied the case fatality rate of unsafe abortion, the
underlying rate of abortion among pregnant women, and the
proportion of abortion that is unsafe. Under base case assump-
tions, the incremental cost-effectiveness ratio associated with
provision of safeabortion for allwomen desiring elective termination
of pregnancy, but with no other changes or improvements in any
dimension of safe motherhood relative to standard care, was
approximately $1,400 per YLS, less than 25% of the GDP per
capita. If the underlying rate of abortion in a pregnant woman is
increased by 1.5, the case fatality rate due to unsafe abortion is
increased to 0.002 or greater, the proportion of unsafe abortion to
safe abortion is increased by 12.5%, and/or if the rate of attributable
morbidity and costs of that morbidity are more than 2 times higher,
the incremental cost-effectiveness ratio associated with provision of
safe abortion is less than 10% of the GDP and in many cases less
than 5% of the GDP (corresponding to cost-effectiveness ratios of
$100 to $500 per YLS or DALY averted).
State-Specific Analyses
When analyzed over ten years (1992 to 2002), the reduction in
maternal mortality rate was 24.4% for high marginality states,
18.9% for medium marginality states, and essentially unchanged
for low marginality states. Results of our cost-effectiveness analyses
repeated for low and high marginality states showed very similar
results to the base case, although the cost savings over the lifetime
of a cohort of 100,000 women ranged from $12.3 to $13 million in
high marginality states and $8.7 to $8.9 million in low marginality
states.
Supplementary results for selected strategies are provided in the
Appendix S1.
Table 3. Maternal outcomes and cost-effectiveness of alternative strategies to improve maternal health compared with status quo
in Mexico.*
..................................................................................................................................................
Strategy
Mortality
(# deaths per
100,000)
Morbidity
(# events per
100,000)
Costs (average
discounted
lifetime)
Life expectancy
(average
discounted)
ICER
($/DALY)
Cost savings relative
to current practice
(per 100,000 women){
Current Practice in Mexico 175 4,149 $502.87 28.6321 --- ---
Current Practice plus increased FP
(33%/74%), safe abortion (100%)
101 (43%) 2,261 (46%) $386.23 28.6446 { $11,600,000
Current Practice plus increased FP
(33%/74%), safe abortion (100%) and
enhanced IpC/EmOC (100%/90%)
43 (75%) 2,204 (47%) $390.21 28.6555 3001 $11,200,000
Current Practice plus increased FP
(33%/74%), enhanced IpC/EmOC
(100%/90%)
62 (64%) 2,769 (33%) $391.30 28.6519 || $11,100,000
Current Practice plus increased FP
(33%/74%)
119 (32%) 2,825 (32%) $397.30 28.6410 || $10,500,000
Current Practice plus safe abortion
(100%) and enhanced IpC/EmOC
(100%/90%)
64 (64%) 3,241 (22%) $493.78 28.6522 || $900,000
Current Practice plus enhanced IpC/
EmOC (100%/90%)
92 (48%) 4,068 (2%) $495.03 28.6472 || $800,000
*DALY=Disability adjusted life years, ICER=incremental cost-effectiveness ratio; IpC=intrapartum care; EmOC=emergency obstetric care; FP=family planning.
Strategies increase coverage of specific interventions above the coverage rates in current practice. These include enhanced high-quality intrapartum care for all
pregnant women (81% to 100%) and enhancing access to comprehensive emergency obstetric care for at least 90% (81% to 90%), safe abortion (from 50% to 100%),
and FP (from 59% to 74% in women age 20 and older, and from 18% to 33% in women younger than age 20). All strategies are compared to current coverage;
incremental cost-effectiveness ratios are assessed by ranking the strategies from the least costly to most costly and calculating the incremental change in costs and
benefits compared to the next best strategy. For strategies that include enhanced IpC/EmOC access we assumed an incremental cost of $18.50 per woman requiring
referral. Also see results section.
{Cost savings relative to current practice (per 100,000 women) is an indicator of the resources that would be saved over the lifetime of a cohort of 100,000 women
relative to current practice in Mexico if a particular strategy was adopted. This savings is calculated as the difference in total lifetime costs for a strategy compared to
current practice, multiplied by 100,000.
{Increased family planning (74% in women age 20 and older, 33% in women younger than age 20) with increased safe abortion (100%) is more effective and less costly
than current practice in Mexico.
1Increased family planning (74% in women age 20 and older, 33% in women younger than age 20) with increased safe abortion (100%) and enhanced IpC/EmOC access
(100%/90%) has a cost-effectiveness ratio of $300/DALY compared to the next best strategy of increased family planning with increased safe abortion alone.
||Strategy is less effective and more costly than increased family planning (74% in women age 20 and older, 33% in women younger than age 20) with increased safe
abortion (100%) and enhanced IpC/EmOC access (100%/90%) and is therefore formally dominated. Compared to current practice, these strategies are still cost saving.
doi:10.1371/journal.pone.0000750.t003
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We developed a flexible decision analytic policy model to simulate
a population of women through their childbearing years,
calibrated the model to country-specific data in Mexico, and
conducted a comparative policy analysis to identify the potential
clinical benefits and cost-effectiveness of alternative strategies for
maternal death and disability reduction in Mexico. Our analysis
extends the work of others [37,49–53] by leveraging primary
national and state-level data available in Mexico, adopting an
analytic approach that considers the risks associated with
pregnancy over a woman’s entire lifetime, and including safe
abortion among the important interventions to consider as part of
a comprehensive strategy to reduce maternal morbidity and
mortality.
The results of our analysis suggest several strategies would
improve maternal health in Mexico and be cost-effective.
Although the mortality reduction with the current coverage levels
for maternal health interventions in Mexico has been substantial
when compared to the national situation several decades ago,
incremental improvements in coverage levels to those recom-
mended in the MBP standard of care, specifically for family planning
and provision of high-quality intrapartum/obstetric care, provide
greater health benefits and save resources. Although the overall
reduction in maternal mortality between 1992 and 2002 in Mexico
approximated only 22%, it was far greater in high- and medium-
marginality states than low-marginality states, indicating that
national efforts were successful in reducing disparities in safe
motherhood within the country.
We also identified several additional strategies involving one or
more incremental improvements to current practice in Mexico
that were capable of providing substantial clinical benefits as well
as cost savings. Among these options, the most effective strategy
consisted of three enhancements to current practice: (1) increasing
family planning from 59% to 74% in women age 20 and older,
and from 18% to 33% in women younger than age 20; (2)
ensuring access to safe abortion for women electing to terminate
a pregnancy; and (3) providing access to intrapartum care for all
pregnant women and enhancing access to comprehensive
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Figure 3. The Impact of Costs Invested in Enhancing Access to EmOC. The additional costs required to enhance access to comprehensive EmOC,
expressed as the composite cost of a successfully referred woman, is assumed to include the costs required for ensuring recognition of the need for
referral, expedient transport, and ultimate access to an appropriate facility capable of comprehensive EmOC. Shown is the impact of varying the cost
per successfully referred woman from $18.50 to $370, on the incremental cost-effectiveness ratios (ICER) for a strategy that includes (1) an increasei n
family planning from 59% to 74% in women age 20 and older, and from 18% to 33% in women younger than age 20, (2) access to safe abortion for all
women who electively terminate a pregnancy; and (3) access to high-quality intrapartum care for all pregnant women and enhanced access to
comprehensive emergency obstetric care for at least 90% of women (pink line), compared with a strategy only focusing on family planning and safe
abortion. Also shown is the impact on the total lifetime savings for a cohort of 100,000 women that could be achieved using this strategy as
compared to current practice in Mexico (blue line). Provided the incremental cost was below $120 per successfully referred woman, the most effective
strategy would be associated with a lower average per-woman lifetime cost than that of current practice (green dashed line). Even at a cost of $185
per successfully referred woman (red solid line), the incremental cost-effectiveness ratio was less than the Mexico-specific GDP per capita, and would
be considered very cost-effective.
doi:10.1371/journal.pone.0000750.g003
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only strategy with enough of an impact to attain the target of 75%
maternal mortality reduction set by Millennium Development
Goal 5.
Also worthy of serious consideration are single- or paired-
intervention strategies involving enhancements in the areas of
family planning, safe abortion, or emergency obstetric care.
Although none of these strategies was ever as attractive as the
package of improvements (family planning, safe abortion and
access to emergency obstetric care), they each would provide
comparable or greater benefit than that made by Mexico on
average in the last decade. Moreover, nearly all strategies would
result in cost-savings over the long-term relative to current
practice. The only exception is the single intervention strategy of
enhanced safe abortion, which, while not cost-saving, would still
be considered highly cost-effective since it has an incremental cost-
effectiveness ratio that is well below Mexico’s GDP per capita of
$6,172 [47]. Of note, a combined approach that improves access
to safe abortion and increases effective coverage for family
planning is synergistic in reducing unwanted pregnancies, re-
ducing maternal morbidity and mortality, and increasing health
returns for investments using public health dollars. The cost
savings from providing these two interventions together, over the
long-term, exceeds $11 million per 100,000 women of reproduc-
tive age followed over their lifetime.
While interventions that improve health at a cost should ideally
be compared with other interventions that compete for the same
resources, there is no universal criterion that defines a threshold
cost-effectiveness ratio, below which an intervention would be
considered cost-effective. A commonly cited rule of thumb is based
on a report by the Commission on Macroeconomics and Health,
following which others suggested that interventions are ‘‘very cost-
effective’’ and ‘‘cost-effective’’ if they have cost-effectiveness ratios
less than per capita GDP or three-times the per capita GDP,
respectively [48]. Given that nearly all strategies we found to be
most effective were also associated with incremental cost-
effectiveness ratios that were only a fraction of Mexico’s GDP
per capita of $6,172 [47], investments in improving maternal
health are likely to be one of the most cost-effective interventions
that could be implemented in Mexico.
Over a short time horizon, additional costs will be required to
implement many of the strategies we identified as cost-effective. In
fact, in the published costing study conducted in Morelos state, the
total cost of upgrading to the WHO Mother Baby Package
standard of care was estimated to be twice that of the current
standard of care [4]. While a costing study provides useful
information for defining current budgetary needs, a cost-effective-
ness analysis aims to identify health investments that provide the
best value given some resource constraint over a long time
horizon. Adopting the latter perspective, we identified several
approaches that would save lives, reduce morbidity, and save
monetary resources compared with current practice. For example,
using current census data from Mexico, our most effective strategy
that included enhanced family planning and safe abortion as two
of its three main components, would save approximately $116
million on average, over the lifetime of a single birth cohort. The
savings in high-marginality states ($49,572,000) would be greater
than those with medium marginality ($39,579,000) or lower
marginality ($26,530,000). While additional short-term funds
might be needed, this analysis provides valuable information to
the Ministry of Health assessing where investment of the next
dollar would make the most difference.
Recently, there has been a published policy statement
supporting implementation of ‘‘effective intrapartum care’’ as first
priority, followed by family planning and safe abortion as
complementary strategies, as the strategic approach with the best
chances of reducing maternal mortality in developing countries
[54]. In addition, attention has been focused on the inclusion of
safe abortion care interventions (which include access to safe
abortion, treatment of abortion complications, and provision of
post-abortion contraception) as a primary strategy in addition to
EmOC for maternal mortality reduction [55,56]. While our results
support the general principles behind these recommendations,
maternal mortality in Mexico is relatively low in comparison to
other developing countries, and this is likely attributable to
a relatively high coverage of, and access to, intrapartum care. Our
analysis indicates that while further improvements in the
intrapartum period, and particularly enhanced access to high-
quality comprehensive emergency obstetrical care, will clearly
prevent maternal deaths, a substantial impact at the state and
national level could be realized by a special focus and effort on
family planning in women of all ages and safe abortion.
Our study has several limitations. There are many data gaps
and the quality of available information was variable. We limited
our analysis to long-term sequelae for which data were accessible
and therefore may have underestimated the burden of disease
related to pregnancy and childbirth in Mexico. We focused on the
interventions included in the WHO Mother Baby Package (MBP)
plus access to safe abortion, in large part because data were
available for many of these. There are others, such as improve-
ments in the management of hypertensive disorders of pregnancy
and enhanced care for women at high-risk because of co-
morbidities, such as diabetes, that were not included. An
advantage of a modeling approach in which a durable tool is
developed and calibrated to a country-specific situation, is that as
better data become available, results may be expediently refined.
These two specific examples will be important data gaps to
remedy.
Second, programmatic costs above and beyond the resources
reflected in the direct medical cost estimates were not included as
they will likely be state-specific and data are not currently
available. Accordingly, priority areas to focus data collection
efforts include the costs of (1) alternative delivery strategies for
family planning and safe abortion, (2) training the provider base
for provision of safe abortion, (3) strategies to improve the quality
of obstetric care, and (4) scaling-up access to comprehensive
EmOC. In general, high marginality states will have greater
resource requirements in terms of overcoming the human resource
and training barriers, as well as in creating the access and
infrastructure necessary to provide improvements in maternal
health strategies, and should be the first priority. In addition, the
resources required for education, advocacy, overcoming cultural
barriers, and political mobilization, all of which would be relevant
for increasing access to safe abortion for example, are not all
monetary, and are certainly complex. That being said, analyses
such as this one, which demonstrate the substantial cost savings
and health gains with safe motherhood interventions, may help to
mobilize political support and advocate for societal change.
Our results may not be generalizable to other countries due to
heterogeneity in risk for poor maternal outcomes, differences in
existing health infrastructure, and differences in the presence and
severity of monetary and nonmonetary constraints [57,58].
Although the qualitative themes we identified are likely to be
robust across regions, operational approaches to delivering care
and strategies to reach the poorest women will likely vary in
different settings. Although future work will expand the choice set
of interventions to include neonatal outcomes, we purposefully
chose to focus on strategies to reduce maternal mortality and
Reducing Maternal Mortality
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quantified, their inclusion would only make these results more
attractive.
There are several strategic options to improve maternal health
in Mexico that would narrow disparities between states and be
cost-effective. Increasing the provision of family planning above
current coverage levels and assurance of access to safe abortion for
all women are complementary and cost-effective strategies that will
provide the greatest benefit within a short-time frame. In the long-
term, aggressive efforts to implement a dually-focused strategy that
reduces both the unmet need for family planning and the risk of
unsafe abortion, saves lives and substantial monetary resources.
Incremental improvement in access to high-quality intra-partum
care within, or with functional rapid linkages to, a setting able to
deliver high-quality care to manage obstetric emergencies will
further reduce maternal deaths and disability. While these
strategies will require additional short-term financial resources,
they will save societal resources in the long-term.
SUPPORTING INFORMATION
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